Hepatitis C replication inhibitors that target the viral NS4B protein

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 2107-2120

  Miller, John F ^a   Chong, Pek Y ^a   Shotwell, J Brad ^a   Catalano, John G ^a   Tai, Vincent W F ^a   Fang, Jing ^a   Banka, Anna L ^a   Roberts, Christopher D ^a   Youngman, Michael ^a,b   Zhang, Huichang ^a   Xiong, Zhiping ^a   Mathis, Amanda ^a,c   Pouliot, Jeffery J ^a   Hamatake, Robert K ^a   Price, Daniel J ^a   Seal, John W ^a   Stroup, Lisa L ^a   Creech, Katrina L ^a   Carballo, Luz H ^a   Todd, Dan ^a   Spaltenstein, Andrew ^a   Furst, Sylvia ^a   Hong, Zhi ^a   Peat, Andrew J ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b LIEBER INSTITUTE FOR BRAIN DEVELOPMENT   (United States)

^c Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; CHIMERIC PROTEIN; HEPATITIS C REPLICATION INHIBITOR; NESBUVIR; NONSTRUCTURAL PROTEIN 4B; PRODRUG; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIPOPHILICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN MODIFICATION; PROTEIN TARGETING; RAT; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; MICE; PRODRUGS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84896296094     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400125h     Document Type: Article

References (72)

1. Te, H. S.; Jensen, D. M. Epidemiology of Hepatitis B and C Viruses: A Global Overview Clin. Liver Dis. 2010, 14, 1-21
2. Shepard, C. W.; Finelli, L.; Alter, M. J. Global Epidemiology of Hepatitis C Virus Infection Lancet Infect. Dis. 2005, 5, 558-567
3. El-Serag, H. B. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma Gastroenterology 2012, 142, 1264-1273
4. Perz, J. F.; Armstrong, G. L.; Farrington, L. A.; Hutin, Y. J. F.; Bell, B. P. The Contributions of Hepatitis B Virus and Hepatitis C Virus Infections to Cirrhosis and Primary Liver Cancer Worldwide J. Hepatol. 2006, 45, 529-538
5. Yeh, W.-S.; Armstrong, E. P.; Skrepnek, G. H.; Malone, D. C. Peginterferon Alfa-2a versus Peginterferon Alfa-2b as Initial Treatment of Hepatitis C Virus Infection: a Cost-Utility Analysis from the Perspective of the Veterans Affairs Health Care System Pharmacotherapy 2007, 27, 813-824
6. Kwong, A. D.; Kauffman, R. S.; Hurter, P.; Mueller, P. Discovery and Development of Telaprevir: An NS3-4A Protease Inhibitor for Treating Genotype 1 Chronic Hepatitis C Virus Nat. Biotechnol. 2011, 29, 993-1003
7. Venkatraman, S. Discovery of Boceprevir, a Direct-Acting NS3/4A Protease Inhibitor for Treatment of Chronic Hepatitis C Infections Trends Pharmacol. Sci. 2012, 33, 289-294
8. Chen, K. X.; Njoroge, F. G. The Journey to the Discovery of Boceprevir: An NS3-NS4 HCV Protease Inhibitor for the Treatment of Chronic Hepatitis C Prog. Med. Chem. 2010, 49, 1-36
9. Russo, M. W.; Fried, M. W. Side Effects of Therapy for Chronic Hepatitis C Gastroenterology 2003, 124, 1711-1719
10. Manns, M. P.; Wedemeyer, H.; Cornberg, M. Treating Viral Hepatitis C: Efficacy, Side Effects, and Complications Gut 2006, 55, 1350-1359
11. Asselah, T.; Marcellin, P. Direct Acting Antivirals for the Treatment of Chronic Hepatitis C: One Pill a Day for Tomorrow Liver Int. 2012, 32 (Suppl. 1) 88-102
12. Welsch, C.; Jesudian, A.; Zeuzem, S.; Jacobson, I. New Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection and Perspectives Gut 2012, 61, i36-i46
13. Pockros, P. J. Drugs in Development for Chronic Hepatitis C: a Promising Future Expert Opin. Biol. Ther. 2011, 11, 1611-1622
14. Fusco, D. N.; Chung, R. T. Novel Therapies for Hepatitis C: Insights from the Structure of the Virus Annu. Rev. Med. 2012, 63, 373-387
15. Lemon, S. M.; McKeating, J. A.; Pietschmann, T.; Frick, D. N.; Glenn, J. S.; Tellinghuisen, T. L.; Symons, J.; Furman, P. A. Development of Novel Therapies for Hepatitis C Antiviral Res. 2010, 86, 79-92
16. Rice, C. M.; Kolykhalov, A. A.; Lin, C.; Reed, K.; Agapov, E. A.; Blight, K.; Xu, J.; Grakoui, A. Virus Hepatitis C Virus Genome Organization and Expression: Potential Antiviral Targets Antiviral Ther. 1996, 1, 11-17
17. Xiong, Y.-L.; Zhang, C.-J.; Wang, X.-H. Hepatitis C Virus Genomic Structure and Function Zhongguo Shengwu Huaxue Yu Fenzi Shengwu Xuebao 2008, 24, 587-592
18. Belzhelarskaya, S. N.; Koroleva, N. N.; Popenko, V. V.; Drutza, V. L.; Orlova, O. V.; Rubtzov, P. M.; Kochetkov, S. N. Hepatitis C Virus Structural Proteins and Virus-like Particles Produced in Recombinant Baculovirus-Infected Insect Cells Mol. Biol. (Moscow, Russ. Fed., Engl. Ed.) 2010, 44, 97-108
19. Beaulieu, P. L.; Llinas-Brunet, M. Therapies for Hepatitis C Infection: Targeting the Non-Structural Proteins of HCV Curr. Med. Chem.: Anti-Infect. Agents 2002, 1, 163-176
20. Mani, N.; Rao, B. G.; Kieffer, T. L.; Kwong, A. D. Recent Progress in the Development of HCV Protease Inhibitors Methods Princ. Med. Chem. 2011, 50, 307-328
21. Chary, A.; Holodniy, M. Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials Rev. Recent Clin. Trials 2010, 5, 158-173
22. Kwo, P. Y.; Vinayek, R. The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors Gut Liver 2011, 5, 406-417
23. Li, H.; Shi, S. T. Non-Nucleoside Inhibitors of Hepatitis C Virus Polymerase: Current Progress and Future Challenges Future Med. Chem. 2010, 2, 121-141
24. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase J. Med. Chem. 2012, 55, 2481-2531
25. Reviriego, C. Daclatasvir Dihydrochloride: Treatment of Hepatitis C Virus HCV NS5A Inhibitor Drugs Future 2011, 36, 735-739
26. Este, J. A.; Cihlar, T. Current Status and Challenges of Antiretroviral Research and Therapy Antiviral Res. 2010, 85, 25-33
27. De Clercq, E. The Design of Drugs for HIV and HCV Nat. Rev. Drug Discovery 2007, 6, 1001-1018
28. Gane, E. J.; Stedman, C. A.; Hyland, R. H.; Phil, D.; Ding, X.; Svarovskaia, E.; Symonds, W. T.; Hindes, R. G.; Berrey, M. M. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C N. Engl. J. Med. 2013, 368, 34-44
29. Stedman, C. A. M. Current Prospects for Interferon-Free Treatment of Hepatitis C in 2012 J. Gastroenterol. Hepatol. 2013, 28, 38-45
30. Rong, L.; Dahari, H.; Ribeiro, R. M.; Perelson, A. S. Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus Sci. Transl. Med. 2010, 2, 1-9
31. Shotwell, J. B.; Baskaran, S.; Chong, P.; Creech, K. L.; Crosby, R. M.; Dickson, H.; Fang, J.; Garrido, D.; Mathis, A.; Maung, J.; Parks, D. J.; Pouliot, J. J.; Price, D. J.; Rai, R.; Seal, J. W.; Schmitz, U.; Tai, V. W. F.; Thomson, M.; Xie, M.; Xiong, Z. Z.; Peat, A. J. Imidazo[1,2- a ]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization ACS Med. Chem. Lett. 2012, 3, 565-569
32. Banka, A.; Catalano, J. G.; Chong, P. Y.; Fang, J.; Garrido, D. M.; Peat, A. J.; Price, D. J.; Shotwell, J. B.; Tai, V.; Zhang, H. Preparation of Piperazinyl Antiviral Agents. WO2011041713A2, April 7, 2011.
33. Banka, A.; Catalano, J. G.; Chong, P. Y.; Fang, J.; Garrido, D. M.; Maynard, A.; Miller, J.; Patterson, D.; Peat, A. J.; Powers, J.; Price, D. J.; Roberts, C.; Tai, V.; Youngman, M. Preparation of 1-Piperidinyl- and 1-Piperazinylpyrazolo[1,5- a ]pyridin-2-ylmethanone Derivatives as Antiviral Agents. WO2011050284A1, April 28, 2011.
34. Rai, R.; Deval, J. New Opportunities in Anti-Hepatitis C Virus Drug Discovery: Targeting NS4B Antiviral Res. 2011, 90, 93-101
35. Gouttenoire, J.; Penin, F.; Moradpour, D. Hepatitis C Virus Nonstructural Protein 4B: A Journey into Unexplored Territory Rev. Med. Virol. 2010, 20, 117-129
36. Cho, N.-J.; Dvory-Sobol, H.; Lee, C.; Cho, S.-J.; Bryson, P.; Masek, M.; Elazar, M.; Frank, C. W.; Glenn, J. S. Identification of a Class of HCV Inhibitors Directed against the Nonstructural Protein NS4B Sci. Transl. Med. 2010, 2, 1-8
37. Dvory-Sobol, H.; Pang, P. S.; Glenn, J. S. The Future of HCV Therapy: NS4B as an Antiviral Target Viruses 2010, 2, 2481-2492
38. Meuleman, P.; Leroux-Roels, G. HCV Animal Models: A Journey of More Than 30 Years Viruses 2009, 1, 222-240
39. Olsen, D. B.; Davies, M.-E.; Handt, L.; Koeplinger, K.; Zhang, N. R.; Ludmerer, S. W.; Graham, D.; Liverton, N.; MacCoss, M.; Hazuda, D.; Carroll, S. S. Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents Antimicrob. Agents Chemother. 2011, 55, 937-939
40. Kikuchi, R.; McCown, M.; Olson, P.; Tateno, C.; Morikawa, Y.; Katoh, Y.; Bourdet, D. L.; Monshouwer, M.; Fretland, A. J. Effect of Hepatitis C Virus Infection on the mRNA Expression of Drug Transporters and Cytochrome p450 Enzymes in Chimeric Mice with Humanized Liver Drug Metab. Dispos. 2010, 38, 1954-1961
41. Kneteman, N. M.; Howe, A. Y. M.; Gao, T.; Lewis, J.; Pevear, D.; Lund, G.; Douglas, D.; Mercer, D. F.; Tyrrell, D. L. J.; Immermann, F.; Chaudhary, I.; Speth, J.; Villano, S. A.; O'Connell, J.; Collett, M. HCV796: A Selective Nonstructural Protein 5B Polymerase Inhibitor with Potent Anti-Hepatitis C Virus Activity in Vitro, in Mice with Chimeric Human Livers, and in Humans Infected with Hepatitis C Virus Hepatology 2009, 49, 745-752
42. Pouliot, J. J.; Thomson, M.; Xie, M.; Horton, J.; Johnson, J.; Krull, D.; Mathis, A.; Morikawa, Y.; Parks, D.; Peterson, R.; Shimada, T.; Thomas, E.; Vamathevan, J.; Van Horn, S.; Xiong, Z.; Hamatake, R.; Peat, A. J. Unpublished results.
43. Roberts, C. D.; Peat, A. J. HCV Replication Inhibitors That Interact with NS4B. In Successful Strategies for the Discovery of Antiviral Drugs; Meanwell, N.; Desai, M. C., Eds.; Royal Society of Chemistry; Cambridge, U.K., 2013; Chapter 6.
44. Carpino, L. A. O -Acylhydroxylamines. II. O -Mesitylenesulfonyl-, O -(p -Toluenesulfonyl)-, and O -Mesitoylhydroxylamine J. Am. Chem. Soc. 1960, 82, 3133-3135
45. Tamura, Y.; Minamikawa, J.; Miki, Y.; Matsugashita, S.; Ikeda, M. A Novel Method for Heteroaromatic N -Imines Tetrahedron Lett. 1972, 13, 4133-4135
46. Anderson, P. L.; Hasak, J. P.; Kahle, A. D.; Paolella, N. A.; Shapiro, M. J. 1,3-Dipolar Addition of Pyridine N -Imine to Acetylenes and the Use of Carbon-13 NMR in Several Structural Assignments J. Heterocycl. Chem. 1981, 18, 1149-1152
47. Kendall, J. D. Synthesis and Reactions of Pyrazolo[1,5- a ]pyridines and Related Heterocycles Curr. Org. Chem. 2011, 15, 2481-2518
48. Loeber, S.; Huebner, H.; Utz, W.; Gmeiner, P. Rationally Based Efficacy Tuning of Selective Dopamine D4 Receptor Ligands Leading to the Complete Antagonist 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5- a ]pyridine (FAUC 213) J. Med. Chem. 2001, 44, 2691-2694
49. Mendiola, J.; Rincon, J. A.; Mateos, C.; Soriano, J. F.; de, F.; Niemeier, J. K.; Davis, E. M. Preparation, Use, and Safety of O -Mesitylenesulfonylhydroxylamine Org. Process Res. Dev. 2009, 13, 263-267
50. 2-2 LiCl: A Chemoselective Base for the Directed Zincation of Sensitive Arenes and Heteroarenes Angew. Chem., Int. Ed. 2007, 46, 7685-7688
51. 2 Chem.-Eur. J. 2009, 15, 457-468
52. Chen, Q.; Wu, S. Methyl (Fluorosulfonyl)difluoroacetate; a New Trifluoromethylating Agent J. Chem. Soc., Chem. Commun. 1989, 705-706
53. Roy, S.; Gregg, B. T.; Gribble, G. W.; Le, V.-D.; Roy, S. Trifluoromethylation of Aryl and Heteroaryl Halides Tetrahedron 2011, 67, 2161-2195
54. Bullock, K.; Chong, P.; Davis, R.; Elitzin, V.; Hatcher, M.; Jackson, M.; Liu, B.; Patterson, D.; Powers, J.; Salmons, M.; Tabet, E.; Toczko, M. Ir C-H Activation and Other Catalysis Applied to a Complex Drug Candidate Top. Catal. 2012, 55, 446-452
55. Chong, P.; Davis, R.; Elitzin, V.; Hatcher, M.; Liu, B.; Salmons, M.; Tabet, E. Synthesis of 7-Trifluoromethylpyrazolo[1,5- a ]pyridinedicarboxylate Tetrahedron Lett. 2012, 53, 6786-6788
56. Ishiyama, T.; Takagi, J.; Ishida, K.; Miyaura, N.; Anastasi, N. R.; Hartwig, J. F. Mild Iridium-Catalyzed Borylation of Arenes. High Turnover Numbers, Room Temperature Reactions, and Isolation of a Potential Intermediate J. Am. Chem. Soc. 2002, 124, 390-391
57. Ishiyama, T.; Nobuta, Y.; Hartwig, J. F.; Miyaura, N. Room Temperature Borylation of Arenes and Heteroarenes Using Stoichiometric Amounts of Pinacolborane Catalyzed by Iridium Complexes in an Inert Solvent Chem. Commun. (Cambridge, U. K.) 2003, 2924-2925
58. Hartwig, J. F. Borylation and Silylation of C-H Bonds: A Platform for Diverse C-H Bond Functionalizations Acc. Chem. Res. 2012, 45, 864-873
59. Leeson, P. D.; Empfield, J. R. Reducing the Risk of Drug Attrition Associated with Physicochemical Properties Annu. Rep. Med. Chem. 2010, 45, 393-407
60. Hann, M. M.; Keserue, G. M. Finding the Sweet Spot: The Role of Nature and Nurture in Medicinal Chemistry Nat. Rev. Drug Discovery 2012, 11, 355-365
61. Meanwell, N. A. Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety Chem. Res. Toxicol. 2011, 24, 1420-1456
62. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
63. Young, R. J.; Green, D. V. S.; Luscombe, C. N.; Hill, A. P. Getting Physical in Drug Discovery II: The Impact of Chromatographic Hydrophobicity Measurements and Aromaticity Drug Discovery Today 2011, 16, 822-830
64. ACD/logD; Advanced Chemistry Development, Inc.: Toronto, Ontario, Canada, 2012.
65. Trachtenberg, E. N.; Carver, J. R. Stereochemistry of Selenium Dioxide Oxidation of Cyclohexenyl Systems J. Org. Chem. 1970, 35, 1646-1653
66. Charette, A. B.; Beauchemin, A. Simmons-Smith cyclopropanation reaction Org. React. 2004, 1-415
67. Friedrich, E. C.; Biresaw, G. Zinc Dust-Cuprous Chloride Promoted Cyclopropanations of Allylic Alcohols Using Ethylidene Iodide J. Org. Chem. 1982, 47, 1615-1618
68. Evans, D. A.; Tedrow, J. S.; Shaw, J. T.; Downey, C. W. Diastereoselective Magnesium Halide-Catalyzed anti-Aldol Reactions of Chiral N -Acyloxazolidinones J. Am. Chem. Soc. 2002, 124, 392-393
69. Ma, B.; Lee, W.-C. A Modified Curtius Reaction: An Efficient and Simple Method for Direct Isolation of Free Amine Tetrahedron Lett. 2010, 51, 385-386
70. Fukuyama, T.; Jow, C.-K.; Cheung, M. 2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines Tetrahedron Lett. 1995, 36, 6373-6374
71. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; Macintyre, F.; Rance, D. J.; Wastall, P. The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data J. Pharmacol. Exp. Ther. 1997, 283, 46-58
72. Jacobson, L.; Middleton, B.; Holmgren, J.; Eirefelt, S.; Froejd, M.; Blomgren, A.; Gustavsson, L. An Optimized Automated Assay for Determination of Metabolic Stability Using Hepatocytes: Assay Validation, Variance Component Analysis, and in Vivo Relevance Assay Drug Dev. Technol. 2007, 5, 403-415